Literature DB >> 7209534

Astatine-211--tellurium radiocolloid cures experimental malignant ascites.

W D Bloomer, W H McLaughlin, R D Neirinckx, S J Adelstein, P R Gordon, T J Ruth, A P Wolf.   

Abstract

An investigation of the efficacy of astatine-211--tellurium colloid for the treatment of experimental malignant ascites in mice reveals that this alpha-emitting radiocolloid can be curative without causing undue toxicity to normal tissue. By comparison, negatron-emitting phosphorus-32 as colloidal chromic phosphate had no antineoplastic activity. The most compelling explanation for this striking difference is the dense ionization and short range of action associated with alpha-emission. These results have important implications for the development and use of alpha-emitters as radiocolloid therapy for the treatment of human tumors.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7209534     DOI： 10.1126/science.7209534

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  15 in total

Review 1.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

2.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

Review 3.  Therapeutic radionuclides: biophysical and radiobiologic principles.

Authors:  Amin I Kassis
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

4.  Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis.

Authors:  George Sgouros; Hong Song
Journal:  Cancer Biother Radiopharm       Date:  2008-02       Impact factor: 3.099

Review 5.  Targeted and Nontargeted α-Particle Therapies.

Authors:  Michael R McDevitt; George Sgouros; Stavroula Sofou
Journal:  Annu Rev Biomed Eng       Date:  2018-01-18       Impact factor: 9.590

6.  Localization of bismuth radiotracer in rat kidney following exposure to bismuth.

Authors:  S Zidenberg-Cherr; M S Clegg; N J Parks; C L Keen
Journal:  Biol Trace Elem Res       Date:  1989-03       Impact factor: 3.738

7.  Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

Authors:  R H Larsen; O S Bruland; P Hoff; J Alstad; E K Rofstad
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

8.  Measurement of the first ionization potential of astatine by laser ionization spectroscopy.

Authors:  S Rothe; A N Andreyev; S Antalic; A Borschevsky; L Capponi; T E Cocolios; H De Witte; E Eliav; D V Fedorov; V N Fedosseev; D A Fink; S Fritzsche; L Ghys; M Huyse; N Imai; U Kaldor; Yuri Kudryavtsev; U Köster; J F W Lane; J Lassen; V Liberati; K M Lynch; B A Marsh; K Nishio; D Pauwels; V Pershina; L Popescu; T J Procter; D Radulov; S Raeder; M M Rajabali; E Rapisarda; R E Rossel; K Sandhu; M D Seliverstov; A M Sjödin; P Van den Bergh; P Van Duppen; M Venhart; Y Wakabayashi; K D A Wendt
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Radionuclide carriers for targeting of cancer.

Authors:  Stavroula Sofou
Journal:  Int J Nanomedicine       Date:  2008

10.  Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.